Chrysostomi Gialeli
- Cardiovascular Research - Translational Studies
- Protein Chemistry, Malmö
- BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
- Cardiovascular Research - Immunity and Atherosclerosis
- EXODIAB: Excellence of Diabetes Research in Sweden
- LUCC: Lund University Cancer Centre
1 – 10 of 17
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Identification of an osteopontin-derived peptide that binds neuropilin-1 and activates vascular repair responses and angiogenesis
(
- Contribution to journal › Article
-
Mark
The prognostic and potentially immunomodulatory role of cartilage oligomeric matrix protein in patients with gastric and esophageal adenocarcinoma
(
- Contribution to journal › Article
-
Mark
CSMD1 regulates brain complement activity and circuit development
(
- Contribution to journal › Article
-
Mark
Tumor suppressor role of the complement inhibitor CSMD1 and its role in TNF-induced neuroinflammation in gliomas
(
- Contribution to journal › Article
-
Mark
Atherosclerotic plaque features relevant to rupture-risk detected by clinical photon-counting CT ex vivo : a proof-of-concept study
(
- Contribution to journal › Article
- 2023
-
Mark
Evaluation of Glycosaminoglycans Biological Age in Cells and Tissues
(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Expression of Cartilage Oligomeric Matrix Protein in colorectal cancer is an adverse prognostic factor and correlates negatively with infiltrating immune cells and PD-L1 expression
(
- Contribution to journal › Article
- 2022
-
Mark
Expression of cartilage oligomeric matrix protein in periampullary adenocarcinoma is associated with pancreatobiliary-type morphology, higher levels of fibrosis and immune cell exclusion
(
- Contribution to journal › Article
- 2021
-
Mark
Extracellular matrix: paving the way to the newest trends in atherosclerosis
(
- Contribution to journal › Article
-
Mark
Complement inhibitor CSMD1 modulates epidermal growth factor receptor oncogenic signaling and sensitizes breast cancer cells to chemotherapy
(
- Contribution to journal › Article